Tiziana Life Sciences Ltd (TLSA)
| Bid | 1.44 |
| Market Cap | 173.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.88M |
| EPS (ttm) | -0.11 |
| PE Ratio (ttm) | -14.18 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.75 |
| Volume | 841,041 |
| Avg. Volume (20D) | 723,511 |
| Open | 1.44 |
| Previous Close | 1.37 |
| Day's Range | 1.42 - 1.68 |
| 52-Week Range | 0.63 - 1.91 |
| Beta | 0.13 |
About TLSA
undefined
1 week ago · proactiveinvestors.com
Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study showsTiziana Life Sciences Ltd (NASDAQ:TLSA)' investigational therapy intranasal foralumab has been shown to significantly reduce neuroinflammation in a 78-year-old patient with moderate Alzheimer's diseas...
2 weeks ago · proactiveinvestors.com
Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumabTiziana Life Sciences Ltd (NASDAQ:TLSA) said on Friday that a patient with moderate Alzheimer's disease showed a marked reduction in brain inflammation after three months of treatment with its lead dr...
2 weeks ago · proactiveinvestors.com
Tiziana shares surge 21% on promising multiple sclerosis dataTiziana Life Sciences Ltd (NASDAQ:TLSA) shares jumped 21% in early trading Tuesday after the company reported positive early-stage data for its experimental multiple sclerosis treatment, nasal foralum...
2 weeks ago · proactiveinvestors.com
Tiziana reports encouraging results for nasal MS drug in early studyTiziana Life Sciences Ltd (NASDAQ:TLSA) said Tuesday that its experimental multiple sclerosis therapy, nasal foralumab, showed positive results in an early-stage study, with patients experiencing stab...
1 month ago · proactiveinvestors.com
Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of MassachusettsTiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the University of Massachusetts has commenced dosing patients in its ongoing Phase 2 trial of its lead candidate intranasal foralumab, a fully hu...
1 month ago · proactiveinvestors.com
Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns HopkinsTiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that Johns Hopkins University has begun dosing patients in its Phase 2 clinical trial evaluating intranasal foralumab for non-active Secondary Pro...
1 month ago · proactiveinvestors.com
Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMSTiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it has begun dosing patients at Yale MS Center in its multicenter Phase 2 trial evaluating intranasal foralumab, a fully human anti-CD3 monoclon...
2 months ago · proactiveinvestors.com
Tiziana Life Sciences nasal anti-CD3 therapy shows promise in treating traumatic brain injury, study revealsTiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a groundbreaking study in Nature Neuroscience that demonstrates promising results for its nasal anti-CD3 therapy in treating tr...
2 months ago · proactiveinvestors.com
Tiziana Life Sciences nearing completion of long COVID study on foralumabTiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it expects to complete its preclinical study evaluating its nasal anti-CD3 foralumab as a potential treatment for long COVID in the second quarte...